KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Non Operating Income: 2010-2025

Historic Non Operating Income for Halozyme Therapeutics (HALO) over the last 16 years, with Sep 2025 value amounting to $5.3 million.

  • Halozyme Therapeutics' Non Operating Income fell 17.62% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 20.29%. This contributed to the annual value of $23.8 million for FY2024, which is 45.57% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Non Operating Income stood at $5.3 million for Q3 2025, which was down 22.61% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Non Operating Income registered a high of $7.3 million during Q4 2024, and its lowest value of -$945,000 during Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Non Operating Income value was $5.3 million (recorded in 2025), while the average stood at $5.4 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Non Operating Income plummeted by 527.60% in 2022 and then soared by 646.65% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Non Operating Income (Quarterly) stood at $331,000 in 2021, then spiked by 157.40% to $852,000 in 2022, then spiked by 529.11% to $5.4 million in 2023, then surged by 35.32% to $7.3 million in 2024, then decreased by 17.62% to $5.3 million in 2025.
  • Its Non Operating Income stands at $5.3 million for Q3 2025, versus $6.9 million for Q2 2025 and $6.8 million for Q1 2025.